(Total Views: 374)
Posted On: 01/04/2020 5:13:29 AM
Post# of 154806
Re: Cytodynamite #14246
Even if we had to put another 30 million shares on the market to get to revenue -
730 million shares x $50 = $36.5b market cap at 5x net sales 7.3b in sales (figured as 50% net sales - royalties).
Expected sales range in combo for U.S. (via Cytodyn) $2.1b - $4.2b, with 50% net sales - 10.5 % royalties = 939m - 1.87b x 2 (for worldwide)
1.87b - 3.74b Well that doesn't get us there.
Combo would fade away when mono is approved - sales $6b - 9b >after net sales and royalties = $2.68b - $4b x 2 = $5.36b - $8b At the top of the range we've surpassed $50 share.
That's in already proven indications. Sit back and think about the additional indications*. Now you can start dreaming, maybe about buying a castle on the Rhine.
*The previous research on CCR5 and those indications proves them out.
730 million shares x $50 = $36.5b market cap at 5x net sales 7.3b in sales (figured as 50% net sales - royalties).
Expected sales range in combo for U.S. (via Cytodyn) $2.1b - $4.2b, with 50% net sales - 10.5 % royalties = 939m - 1.87b x 2 (for worldwide)
1.87b - 3.74b Well that doesn't get us there.
Combo would fade away when mono is approved - sales $6b - 9b >after net sales and royalties = $2.68b - $4b x 2 = $5.36b - $8b At the top of the range we've surpassed $50 share.
That's in already proven indications. Sit back and think about the additional indications*. Now you can start dreaming, maybe about buying a castle on the Rhine.
*The previous research on CCR5 and those indications proves them out.
(3)
(0)
